NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
This article was originally published in The Tan Sheet
Executive Summary
NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act
You may also be interested in...
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry